Skip to main content

Table 2 Ongoing Clinical Trials in Anaplastic Thyroid Cancer (as on July 15, 2018), listed from https://clinicaltrials.gov/

From: Therapeutic advances in anaplastic thyroid cancer: a current perspective

S. No Phase Drug Drug Action Clinical Trial No. Status Sponsors
1 II MLN0128 mTOR kinase inhibitor NCT02244463 Recruiting Dana-Farber Cancer Institute, USA
2 II Lenvatinib MKI against VEGFR1, 2, and 3 NCT02726503 Recruiting Translational Research Informatics Center, Kobe, Hyogo, Japan
NCT02657369 Recruiting Eisai Inc. USA
3 Early phase I Trametinib in combination with Paclitaxel MEK inhibitor (Trametinib) with chemotherapy NCT03085056 Recruiting Memorial Sloan Kettering Cancer Center, USA
4 II Pembrolizumab Antibody against PD-1 receptor NCT02688608 Recruiting University of Texas Southwestern Medical Center, USA
5 II Inolitazone Dihydrochloride (Efutazone) and Paclitaxel PPAR-γ agonist (Efutazone) with chemotherapy NCT02152137 Recruiting Alliance for Clinical Trials in Oncology, USA
6 I Combination of Durvalumab (MEDI4736) or Tremelimumab with Stereotactic Body Radiotherapy (SBRT) Checkpoint inhibitor drugs: Durvalumab (PD-1/PDL-1 interaction blocker) and Tramelimumab (anti-CTLA4 antibody) with radiations NCT03122496 Recruiting Memorial Sloan Kettering Cancer Center, USA
7 II Intensity-Modulated Radiation Therapy and Paclitaxel with or Without Pazopanib Hydrochloride Pazopanib is a MKI against c-kit, FGFR, PDGFR and VEGFR NCT01236547 Ongoing but not yet recruiting participants National Cancer Institute (NCI), USA
8. II Ceritinib ALK inhibitor NCT02289144 Recruiting University of Texas Southwestern Medical Center, USA
9 II Atezolizumab Combinations with or without chemotherapy such as paclitaxel, Vemurifinib, Nab-paclitaxel, Cobimetinib and Bevacizumab anti-PDL-1 antibody (Atezolizumab) NCT03181100 Recruiting M.D. Anderson Cancer Center, USA
10 I FAZ053 as Single Agent and in combination with PDR001 FAZ053 is anti-PDL-1 antibody and PDR001 is monoclonal antibody against PD-1. NCT02936102 Recruiting Novartis Pharmaceuticals, USA
11 II Dabrafenib and Trametinib Dabrafenib acts against BRAFV600E mutations and Trametinib is MEK (1 and 2) inhibitor NCT02034110 Recruiting GlaxoSmithKline, USA
12 II GW 786034 (Pazopanib Hydrochloride) Pazopanib is a MKI against c-kit, FGFR, PDGFR and VEGFR NCT00625846 Active, not recruiting National Cancer Institute (NCI), USA
13 II Pembrolizumab, Chemotherapy,and Radiation Therapy With or Without Surgery anti-PD1 immunotherapy NCT03211117 Active, not recruiting Mayo Clinic,National Cancer Institute (NCI), USA
14 I/II PDR001 anti-PD1 monoclonal antibody NCT02404441 Recruiting Novartis Pharmaceuticals